GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Total Operating Expense

Cerevel Therapeutics Holdings (STU:673) Total Operating Expense : €452.91 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Total Operating Expense?

Cerevel Therapeutics Holdings's Total Operating Expense for the three months ended in Mar. 2024 was €131.24 Mil. Cerevel Therapeutics Holdings's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €452.91 Mil.

Cerevel Therapeutics Holdings Total Operating Expense Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Total Operating Expense Chart

Cerevel Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
75.12 122.57 194.79 347.25 410.14

Cerevel Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.98 89.39 104.30 127.98 131.24

Cerevel Therapeutics Holdings Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €452.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cerevel Therapeutics Holdings Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Total Operating Expense
Comparable Companies
PCVX HALO BBIO IMVT MRTX ABCZF ASND ACAD IMGN BPMC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CERE:USA
Address
222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141
Website
https://www.cerevel.com
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines